^
    7d
    Exploring angiogenic pathways in breast cancer: Clinicopathologic correlations and prognostic implications based on gene expression profiles from a large-scale genomic dataset. (PubMed, PLoS One)
    In this dataset of patients with breast cancer, the expression levels of 8 different pro-angiogenic genes revealed remarkable differences in terms of their association with clinicopathologic tumor characteristics and prognosis. The expression of ANGPTs and PDGFs was associated with adverse tumor features, worse prognosis, and reduced survival in patients. Targeting ANGPTs and PDGF pathways could provide new insights for effective anti-angiogenic drugs in breast cancer.
    Journal • Gene Expression Profile
    |
    HER-2 (Human epidermal growth factor receptor 2) • HGF (Hepatocyte growth factor) • ANGPT2 (Angiopoietin 2) • FGF2 (Fibroblast Growth Factor 2) • PDGFA (Platelet Derived Growth Factor Subunit A) • PDGFB (Platelet Derived Growth Factor Subunit B)
    |
    HER-2 positive • HR negative • VEGFA expression • FGF1 expression • HER-2 positive + HR negative
    7d
    Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer. (PubMed, Am J Case Rep)
    The TCbHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) as neoadjuvant chemotherapy was given. Our clinical experience suggests that neoadjuvant chemotherapy followed by modified radical mastectomy can be effective for treating such rare cases. The patient achieved pCR, which can provide a therapeutic strategy for effective treatment of similar OBCs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR negative • HER-2 positive + HR negative
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab)
    8d
    Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis. (PubMed, J Clin Oncol)
    These results suggest there are both subtype-specific and subtype-independent mechanisms that contribute to disparities in breast cancer survival between Black and White women, which require multilevel interventions to address and achieve health equity.
    Retrospective data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative
    8d
    Trastuzumab deruxtecan (T-DXd) with pyrotinib in First-line HER2-positive unresectable or metastatic breast cancer: an exploratory, single-arm, multi-center trial (ChiCTR2400087692)
    P=N/A, N=51, Not yet recruiting, Peking University First Hospital; Peking University First Hospital
    New trial • Metastases
    |
    HER-2 positive • HR positive • HER-2 positive + HR negative
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Irene (pyrotinib)
    9d
    IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
    P1/2, N=29, Recruiting, University of Florida | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative • HR negative + HER-2 positive
    |
    Tecentriq (atezolizumab) • Fotivda (tivozanib)
    17d
    HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome. (PubMed, Eur J Cancer)
    Among females with LFS and BC, HER2-positive subtype was associated with younger age at diagnosis and a predominant HR-positivity. Favorable pCR rates were observed among those receiving neoadjuvant HER2-directed therapies, for both HR-positive and negative tumors. These data may inform the counseling and care of patients with LFS.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 negative + HR negative • HER-2 positive + HR negative
    |
    Herceptin (trastuzumab)
    22d
    Incidence of Pathologic Nodal Disease in Clinically Node-Negative, Microinvasive or T1a Breast Cancers. (PubMed, Ann Surg Oncol)
    Over 90% of patients with clinically node-negative, microinvasive and T1a breast cancer remain pathologically node-negative following axillary staging. However, higher rates of nodal disease were found among Black patients, older patients, and patients with lobular cancer and significant comorbidities.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR negative • EGFR positive • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + HR negative • HER-2 positive + HR negative